Fate Therapeutics Updates FT819 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy FATE?
Fate Therapeutics presented updated clinical data from its ongoing Phase 1 trial evaluating its FT819 off-the-shelf iPSC-derived CAR T-cell program in systemic lupus erythematosus and unveiled new preclinical data from next-generation off-the-shelf iPSC-derived CAR T-cell programs for hematologic malignancies and autoimmune diseases at the 2025 American Society of Hematology Annual Meeting & Exposition in Orlando, Florida. Key highlights: FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus patients now treated; first systemic sclerosis patient treated; First ex-U.S. SLE patient treated with FT819 expands enrollment capacity and supports unique ability of FT819 for broad, on-demand patient accessibility; Preclinical studies show FT836 chimeric antigen receptor T cells uniquely targeting stress antigens MICA/B, combined with daratumumab, provide a comprehensive approach to treatment of multiple myeloma; FT839 CAR T cells demonstrate the unique ability to treat a wide range of B-cell malignancies and autoimmune diseases through dual-CAR CD19/CD38 targeting without the need of conditioning chemotherapy in various preclinical models; combination with monoclonal antibodies or T-cell engager further expands targeting capacity
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FATE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FATE
Wall Street analysts forecast FATE stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 1.500
Low
2.00
Averages
4.64
High
8.00
Current: 1.500
Low
2.00
Averages
4.64
High
8.00
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
- Q4 Revenue: Fate Therapeutics reported $1.4 million in revenue for Q4 2025, indicating a decline compared to the previous year, yet demonstrating the company's ongoing operational capability in the biopharmaceutical sector.
- Cash and Investment Position: As of December 31, 2025, the company held $205.1 million in cash, cash equivalents, and investments, providing a robust financial foundation for future R&D and market expansion efforts.
- Financial Stability: The company has maintained a solid cash flow position in the current economic environment, ensuring its competitiveness in the biotechnology industry and laying the groundwork for potential collaborations and acquisition opportunities.
- Market Outlook: Despite facing challenges, Fate Therapeutics remains committed to advancing its innovative therapies, with expectations to enhance revenue and shareholder value through new product launches and market expansion in the future.
See More
FT819 CAR T-Cell Therapy Achieves Significant Milestone
- Clinical Trial Expansion: The Phase 1 trial of FT819 is now enrolling patients across 16 clinical sites in the U.S., U.K., and EU, with 15 systemic lupus erythematosus patients enrolled to date, indicating strong interest in FT819's safety and efficacy, which is expected to drive future commercialization efforts.
- Outpatient Treatment Innovation: The successful application of FT819 allows autoimmune patients to receive CAR T-cell therapy on an outpatient basis, eliminating the need for hospitalization, which not only enhances patient accessibility but also significantly improves healthcare system economics.
- Strong Financial Position: As of December 31, 2025, the company reported $205 million in cash and cash equivalents, projected to support clinical and collaboration milestones through 2027, while a 30% reduction in operating expenses in 2025 compared to 2024 further enhances financial flexibility.
- Significant Clinical Outcomes: The first systemic sclerosis patient treated with FT819 showed meaningful disease improvement at the 3-month evaluation using less-intensive conditioning chemotherapy, highlighting FT819's potential and efficacy in treating autoimmune diseases.
See More
Fate Therapeutics Inc. Forecasts Operating Runway Until End of 2027, Backed by $205 Million in Cash and Investments
Project Overview: The project aims to establish a therapeutic operating runway through the year-end of 2027.
Financial Support: It is backed by $205 million in cash, cash equivalents, and investments.
See More
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
- Active Clinical Pipeline: Over 12 companies are currently developing more than 15 iPSC-derived NK cell drugs, indicating robust growth potential in this field, which is expected to drive innovation and market expansion in cancer immunotherapy.
- Key Company Involvement: Major pharmaceutical firms, including Centuary Therapeutics and Fate Therapeutics, are evaluating new drugs aimed at improving treatment outcomes and meeting the increasing market demand, thereby solidifying their market positions.
- Clinical Data Release: Century Therapeutics' CNTY-101 has shown preliminary results in the CARAMEL trial, with initial data expected to be presented on December 5, 2025, indicating potential for treating B-cell-mediated autoimmune diseases, which may attract further investment and attention.
- Strategic Collaboration Agreement: The joint development agreement between ViGenCell and Therabest for TB-420 to treat hepatocellular carcinoma involves a contract fee of 4 billion won (approximately $2.8 million), enhancing the depth of technological collaboration and potentially laying the groundwork for future market expansion.
See More
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
- Q4 Revenue: Fate Therapeutics reported $1.4 million in revenue for Q4 2025, indicating a decline compared to the previous year, yet demonstrating the company's ongoing operational capability in the biopharmaceutical sector.
- Cash and Investment Position: As of December 31, 2025, the company held $205.1 million in cash, cash equivalents, and investments, providing a robust financial foundation for future R&D and market expansion efforts.
- Financial Stability: The company has maintained a solid cash flow position in the current economic environment, ensuring its competitiveness in the biotechnology industry and laying the groundwork for potential collaborations and acquisition opportunities.
- Market Outlook: Despite facing challenges, Fate Therapeutics remains committed to advancing its innovative therapies, with expectations to enhance revenue and shareholder value through new product launches and market expansion in the future.
See More
FT819 CAR T-Cell Therapy Achieves Significant Milestone
- Clinical Trial Expansion: The Phase 1 trial of FT819 is now enrolling patients across 16 clinical sites in the U.S., U.K., and EU, with 15 systemic lupus erythematosus patients enrolled to date, indicating strong interest in FT819's safety and efficacy, which is expected to drive future commercialization efforts.
- Outpatient Treatment Innovation: The successful application of FT819 allows autoimmune patients to receive CAR T-cell therapy on an outpatient basis, eliminating the need for hospitalization, which not only enhances patient accessibility but also significantly improves healthcare system economics.
- Strong Financial Position: As of December 31, 2025, the company reported $205 million in cash and cash equivalents, projected to support clinical and collaboration milestones through 2027, while a 30% reduction in operating expenses in 2025 compared to 2024 further enhances financial flexibility.
- Significant Clinical Outcomes: The first systemic sclerosis patient treated with FT819 showed meaningful disease improvement at the 3-month evaluation using less-intensive conditioning chemotherapy, highlighting FT819's potential and efficacy in treating autoimmune diseases.
See More
Fate Therapeutics Inc. Forecasts Operating Runway Until End of 2027, Backed by $205 Million in Cash and Investments
Project Overview: The project aims to establish a therapeutic operating runway through the year-end of 2027.
Financial Support: It is backed by $205 million in cash, cash equivalents, and investments.
See More
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
- Active Clinical Pipeline: Over 12 companies are currently developing more than 15 iPSC-derived NK cell drugs, indicating robust growth potential in this field, which is expected to drive innovation and market expansion in cancer immunotherapy.
- Key Company Involvement: Major pharmaceutical firms, including Centuary Therapeutics and Fate Therapeutics, are evaluating new drugs aimed at improving treatment outcomes and meeting the increasing market demand, thereby solidifying their market positions.
- Clinical Data Release: Century Therapeutics' CNTY-101 has shown preliminary results in the CARAMEL trial, with initial data expected to be presented on December 5, 2025, indicating potential for treating B-cell-mediated autoimmune diseases, which may attract further investment and attention.
- Strategic Collaboration Agreement: The joint development agreement between ViGenCell and Therabest for TB-420 to treat hepatocellular carcinoma involves a contract fee of 4 billion won (approximately $2.8 million), enhancing the depth of technological collaboration and potentially laying the groundwork for future market expansion.
See More
